single molecule array

The firm sold more than 4.9 million shares of common stock at $15 per share, raising $73.7 million to expand its commercial operations and grow its technology.

Quanterix Plans IPO

The firm plans to use the proceeds to expands its commercial operations, expand its existing technology, and support the launch of its new platform.

The funding was led by T. Rowe Price and will be used by Quanterix to develop new instruments, expand the firm's assay menu, and other things. 

ImmunArray will use Quanterix's Simoa single-molecule array technology for biomarker analysis, with the potential to enrich its diagnostic panels.

The company will develop the assays for its single-molecule array technology and incorporate the markers into multiplex assays for research use in neurology.

Three new investors joined existing investors in leading the round, which will fund desktop instrument development, international sales, and assay menu expansion.

As Quanterix continues to grow its business, quantifying proteins in single cells could drive its sales in the academic market, CEO Kevin Hrusovsky said.

The firm has signed an exclusive agreement for China with Cold Spring Biotech and a deal for Singapore, Thailand, and Malaysia with Research Instruments.

The firm has re-engineered hardware and redesigned software to improve its single-molecule array platform and has increased its multiplexing capabilities.

Quanterix has won a second GE NFL Head Health Challenge I grant and will use it to develop diagnostics with biomarkers discovered under the first grant.

Pages

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.